Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.
Ziconotide, a potent, selective, reversible blocker of neuronal N-type voltage-sensitive calcium channels, is approved in the United States for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. In the European Union, ziconotide is indicated for the treatment of severe chronic pain in patients who require intrathecal analgesia. Nonclinical investigations of ziconotide included a comprehensive characterization of its toxicology, incorporating acute and subchronic toxicity studies in rats, dogs, and monkeys; reproductive toxicity assessments in rats and rabbits; and mutagenic, carcinogenic evaluations performed in vivo and in vitro. Additional investigations assessed the potential for cardiotoxicity (rats) and immunogenicity (mice, rats, and guinea pigs), and the presence or absence of intraspinal granuloma formation and local cell proliferation and apoptosis (dogs). The resulting nonclinical toxicology profile was predictive of human adverse events reported in clinical trials and consistent with ziconotide's pharmacological activity. Frequently observed nonclinical behavioral effects included tremoring, shaking, ataxia, and hyperreactivity. Occurrences were generally transient and reversible upon cessation of treatment, and intolerable effects occurred at doses more than 45 times the maximum recommended clinical dose. Ziconotide was not associated with target organ toxicity, teratogenicity, or treatment-related gross or histopathological changes; it displayed no mutagenic or carcinogenic potential and no propensity to induce local cell proliferation or apoptosis. Although guinea pigs developed systemic anaphylaxis, antibodies to ziconotide were not detected in mice, rats, or guinea pigs, indicating low immunogenic potential. No evidence of granuloma formation was observed with intrathecal ziconotide treatment. In summary, the results from these nonclinical safety assessments revealed no significant toxicological risk to humans treated with ziconotide as recommended.
Skov
Michael J
MJ
Elan Pharmaceuticals, Inc., South San Francisco, California 94080, USA. michael.skov@elan.com
Beck
James C
JC
de Kater
Annelies W
AW
Shopp
George M
GM
D000595:Amino Acid Sequence; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D000818:Animals; D015197:Carcinogenicity Tests / Q000379:methods; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D047108:Embryonic Development / Q000187:drug effects; D047109:Fetal Development / Q000187:drug effects; D006168:Guinea Pigs; D007261:Infusions, Intra-Arterial; D007278:Injections, Spinal; D008252:Macaca fascicularis; D051379:Mice; D008815:Mice, Inbred Strains; D008969:Molecular Sequence Data; D009152:Mutagenicity Tests / Q000379:methods; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity; D023382:Toxicity Tests, Acute / Q000379:methods; D036401:Toxicity Tests, Chronic / Q000379:methods; D020960:omega-Conotoxins / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*
D018712:Analgesics, Non-Narcotic; D020960:omega-Conotoxins; C078452:ziconotide